NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market.

The initial product orders were placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region. Tapping into the growing interest in safety syringe technology in Latin America, the collaboration will make the Securegard syringe line available to hospitals, pharmacies, and direct points of sale and will give healthcare networks access to utilizing the technology and firsthand experience with its real-world benefits.

“This shipment is a great step in building strategic partnerships within the entire Latin American distribution network and supporting region-wide efforts to improve medical safety and healthcare outcomes,” comments Robert Hayes, Sharps Technology CEO. “While implementing wide-scale change can be challenging, based on our studies we are confident that once healthcare practitioners use Securegard syringes, they will want to continue to use them, leading to long-term purchase orders and deliveries.”

Securegard syringes provide clinicians with an ultra-low waste drug delivery technology that incorporates active safety features as well as World Health Organization accredited re-use prevention measures. These features maximize the amount of drug therapy that is available to patients while both protecting frontline healthcare workers from life-threatening needle stick injuries and protecting the public from the dangers of needle re-use. The introduction of Securegard technology into Latin America can greatly enhance the overall quality level of healthcare available in that market.

Securegard syringes offer a promising drug delivery solution for healthcare markets, facilities, and providers by incorporating safety and re-use prevention features into their design. Moreover, the use of ultra-low waste syringe technology ensures that the maximum number of doses of needed drug therapies can be made available to the people who depend on them. This is not only beneficial for healthcare professionals and patients across the vast Latin American market, but also sets a positive example for other regions to follow in adopting sustainable and safe medical practices.

For additional information on Sharps Technology and its Securegard smart safety syringes, please visit www.sharpstechnology.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Investor Relations:
Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-644-4256
This email address is being protected from spambots. You need JavaScript enabled to view it.